Core Laboratories Posts Sequential Revenue Growth, EPS Gains and Solintec Acquisition
Core Laboratories reported sequential revenue growth with improved operating income, margins and EPS and cut leverage to a nine-year low after acquiring Brazil-based Solintec. The company returned capital via dividends and buybacks and now has a market capitalization of about $736 million following a one-month return of -15.49%.
1. Sequential Revenue Growth
Core Laboratories reported another quarter of sequential revenue growth driven by strong global demand for proprietary reservoir description and production enhancement services, resulting in improved operating income, expanded profit margins and higher EPS.
2. Solintec Acquisition
The company expanded its international footprint through the acquisition of Brazil-based Solintec, integrating its testing and diagnostic services to strengthen service offerings in the Latin American market.
3. Leverage Reduction and Capital Returns
Core Laboratories reduced its net debt to the lowest level in nine years and returned capital to shareholders via regular dividends and share buybacks, underpinned by a disciplined focus on free cash flow and debt reduction.
4. Market Performance and Valuation
Shares of Core Laboratories fell 15.49% over the past month, trading between $9.72 and $20.36 during the last 52 weeks and closing at approximately $16.11 on March 5 with a market capitalization near $736 million.